Peer review process
Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the editors and peer reviewers.
Read more about eLife’s peer review process.Editors
- Reviewing EditorVolker DötschGoethe University Frankfurt, Frankfurt am Main, Germany
- Senior EditorVolker DötschGoethe University Frankfurt, Frankfurt am Main, Germany
Reviewer #1 (Public Review):
Summary:
Kinase inhibitors represent a highly valuable class of drugs as evidenced by their continued clinical success. The target landscape of kinase targeting small molecules can be leveraged to alter multiple phenotypes with increasing complexity that broadly aligns with increasing target promiscuity. This 'tools and resources' contribution provides a starting point for researchers interested in aligning kinase inhibitor activity with cytokine/chemokine stimulated signal transduction networks.
Strengths:
KinCytE is a forward-thinking database that yields hypothesis-generating options for researchers interested in pharmacologically modulating cytokine/chemokine signaling.
Weaknesses:
As a 'tools and resources' contribution, the primary (potential) weakness will be the authors' willingness to update and improve the tool. KinCytE will require frequent updating to better inform users in terms of contextual cytokine/chemokine stimulated signaling and the target landscape of those agents that are included as options.
Reviewer #2 (Public Review):
Summary:
In this manuscript, "KinCytE- a Kinase to Cytokine Explorer to Identify Molecular Regulators and Potential Therapeutic", the authors present a web resource, KinCytE, that lets researchers search for kinase inhibitors that have been shown to affect cytokine and chemokine release and signaling networks. I think it's a valuable resource that has a lot of potential and could be very useful in deciding on statistical analysis that might precede lab experiments.
Opportunities:
With the release of the manuscript and the code base in place, I hope the authors continue to build upon the platform, perhaps by increasing the number of cell types that are probed (beyond macrophages). Additionally, when new drug-response data becomes available, perhaps it can be used to further validate the findings. Overall, I see this as a great project that can evolve.
Strengths:
The site contains valuable content, and the structure is such that growing that content should be possible.
Weaknesses:
Only based on macrophage experiments, would be nice to have other cell types investigated, but I'm sure that will be remedied with some time.